A good trail result offset by a poor Trail design and implementation. They knew the scar are +12 years old but still went ahead, and only 3 months. If they enrolled younger scars for 3 more months the result would be fantastic.
A big thumb up for the drug but a thumb down for Gary's skill of management and Quality Control, PXS is too small to waste time and fund like this.
Much younger scars for 6 months will definitely see the trail with huge success. the share price should be 10 times more than it is now.
PXS Price at posting:
4.9¢ Sentiment: Buy Disclosure: Held
